Q&A w/ Paul Dreier and VisionTech Partners

VisionTech, one of the Midwest’s most active angel investing groups, recently featured Novilytic on their blog. The post was presented in Q&A format with Paul Dreier, CEO, being the spokesperson for our company.

The questions are bulleted below and a link to the entire piece with Paul’s answers can be found here: Meet July Pitch Presenter #2: Paul Dreier of Novilytic, the Canary in Pharma’s Coal Mine – VisionTech Partners

• Your chief technology officer who developed Novilytic’s technology, Dr. Fred Regnier, is a legend in chemistry and at Purdue. How did you two connect?
  

• Tell me about Novilytic and the unmet need you’re addressing.
  

• You have a clever brand story. Tell me about it.
  

• Explain how your Proteometer works. Is it a device? A process?
  

• What are your competitive advantages?
  

• Do you have any patent protection?
  

• What’s your total addressable market? Are there any secondary markets you might pursue?
  

• What’s your revenue model?
  

• Where are you with commercialization?
  

• What funding round is this?
  

• What is your planned use of funds?
  

• Give three reasons why VisionTech Angels should invest?

We thank VisionTech for their time and for helping us to spread the word about our critical mission!